Loading
Latest filing published 26 Jan 2024 for Rain Oncology Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Robert Doebele (chief executive) discloses dealings in Rain Therapeutics Inc. to SEC (Form 4). We count 5 filings; the first trade dates from 27 April 2021 and the latest from 26 January 2024.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 26 January 2024, the filings show a transaction in Rain Therapeutics Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations